Provider review
Freeley review
By The Dose Brief Desk · Updated
Freeley’s $179 GLP-1 headline is tied to a 24-month plan. Establish the total obligation before comparing it with month-to-month care.
Not rated. This review examines published program information; it is not a firsthand treatment review.
At a glance
- Semaglutide
- $179 GLP-1 headline applies to a 24-month plan; medication-specific quote unconfirmed
- Tirzepatide
- Medication-specific quote unconfirmed
- Availability
- Confirm state and selected-product availability.
- Treatment formats
- GLP-1 treatment; exact prescription and formulation require confirmation.
A two-year plan qualifies the advertised starting rate; clarify upfront payment, renewal and early-exit terms.
The two-year qualification belongs beside the price
Freeley’s pricing page advertises GLP-1 treatment from $179 on a 24-month plan. A two-year commitment is materially different from a cancelable monthly order. Ask for the total payable amount, billing schedule and consequences of leaving before the term ends.
Do not assume the headline names your medication
The reviewed price did not establish the same rate for every semaglutide or tirzepatide option, formulation or dose. Request the exact prescription and included supply in writing. Otherwise the comparison risks matching a general starting offer with another provider’s specific ongoing price.
What Freeley says is included
The page describes a physician-and-pharmacy care bundle with delivery and a refund when clinical evaluation declines treatment. That denial provision should be distinguished from refunds after a prescription has been approved and medication prepared.
Reconcile flexibility claims with the plan
General no-contract language does not explain the obligations attached to the 24-month offer. Ask which written terms govern your selection, when medication is dispensed and whether unused future supply is refundable. Those answers are necessary before judging the discount against the value of a shorter commitment.
What stands out
- Long-plan qualification is publicly identifiable
- Clinical-denial refund is described
What to check
- Lowest headline requires a 24-month plan
- Medication mapping and early-exit terms need clarification
Sources and review scope
Public information checked in October 2026. Prices and eligibility can change. We have not enrolled in treatment, independently tested medications or verified the licenses of the clinicians and pharmacies involved in an individual prescription. Compounded medications are not FDA-approved; studies of approved brands do not establish that a compounded product has the same safety or effectiveness.